Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telehealth-supported pharmacy delivery of PrEP and PEP in Kenya
PACTR202608477604439Phase 4Not yet recruiting
- Sponsor
- National Institutes of Health
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institutes of Health. Primary endpoints: Number of PrEP/PEP initiations and Number of PrEP/PEP continuations. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202608477604439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608477604439.